Rationally designed protein compositions
US12378295B2 · kind B2 · utility
0Cited by
5References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 29, 2019 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Sep 6, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel compositions and methods relating to or derived from a rationally designed fusion protein composition combines a therapeutic antibody with an IL2 mutant that can simultaneously enhance anti-tumor immunity or derepress tumor-associated immunosuppression along with direct activation of effector cells by IL2 without activating Treg are provided. The fusion protein can be used to prevent or therapeutically treat cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.